| Factor | Score | Distribution | Value | Avg | Rank |
|---|---|---|---|---|---|
Valuation | 35 | 49.4x | 17.8x | Bottom tier | |
Growth | 40 | 0.4% | 7.1% | Bottom tier | |
Quality | 81 | 5.6% | 4.5% | Top tier | |
Safety | 54 | 3.8x | 2.6x | Around median | |
Capital Return | 89 | — | 2.12% | Top tier | |
Momentum | 95 | 53.9% | 2.9% | Top tier | |
Sentiment | 81 | 9 | 3 | Top tier |
Estimates — analyst targets and a simplified DCF, not investment advice.
Ten ratios that matter, each compared against its sector median and average — so you can see whether a number is rich or cheap relative to peers in the same sector.
Haemonetics Corporation develops technologies and products for blood and plasma management and interventional procedures, and generates revenue from related devices, consumables, and software. Under the segment structure announced on June 5, 2026, its operations are divided into MedSurg and Apheresis; its main platforms include Persona PLUS for plasma collection, the TEG system and Hemostasis assays, Transfusion Management software, and the VASCADE MVP and VASCADE MVP XL vascular closure products. The high weighting of recurring consumables and software helps improve revenue quality compared with capital sales alone.
In Q1 fiscal 2027, revenue reached $339 million, up 6% on both a reported and organic basis, while adjusted diluted earnings per share increased 4% to $1.14. MedSurg generated revenue of $148 million and reported and organic growth of 6%, while Apheresis generated revenue of $191 million, or about 56% of total revenue, with reported growth of 5% and organic growth of 6%. Within Apheresis, Plasma revenue grew 8% organically, while revenue from other activities declined 3% organically.
Gross margin in Q1 fiscal 2027 was approximately 60.4%, down 40 basis points, while adjusted operating margin was 23.4%, down 70 basis points year over year and 100 basis points from the previous quarter. Management explained that the year-over-year comparison was affected by an upfront software benefit that improved the comparable-period margin by approximately 200 basis points, and that adjusted gross margin expanded after excluding it. For the annual comparison, Haemonetics recorded revenue of $1.3 billion, gross profit of $787.6 million, net income of $97.3 million, and earnings per share of $2.05 in fiscal 2026.
Automated analysis for informational purposes only — not investment advice.
The average analyst price target is $104.6, compared with a wide target range of $85 to $119 and a consensus rating of “Buy.” The average target is approximately 4.5% below the top of the 52-week range of $109.57, while the highest target exceeds that peak. The breadth of the target range reflects uncertainty between the strength of Plasma and Persona PLUS growth on one hand and margin pressures and competition on the other. The 52-week range is between $47.32 and $109.57, highlighting that the revaluation has been associated with fluctuating growth expectations and the Vascular Closure recovery rather than a steady operating trajectory.
Figures in the text are as of 2026-08-30; the live price is shown at the top of the page.
Haemonetics’ Q1 fiscal 2027 revenue reached approximately $339 million, up 6% on both a reported and organic basis, while adjusted diluted earnings per share increased 4% to $1.14. MedSurg revenue grew 6% to $148 million, while Apheresis revenue increased 6% organically to $191 million. Plasma was the most prominent driver, with organic growth of 8%, alongside 8% organic growth in Blood Management Technologies and a return to 3% organic growth in Interventional Technologies.
Persona PLUS is a firmware upgrade for the plasma collection platform, and its early users achieved a yield improvement exceeding 5% compared with previous Persona offerings. In August 2026, the company was converting between 30 and 40 centers per week and said implementation was progressing faster than planned. The upgrade, together with market share gains and strong collection volumes, contributed to 8% organic Plasma growth during Q1 fiscal 2027, but the guidance includes only contracts and timelines for which management has clear visibility.
Vascular Closure grew in the low double digits year over year during Q1 fiscal 2027 after the company lost a number of important accounts in Q1 fiscal 2026. VASCADE MVP and MVP XL supported this recovery, alongside the expansion of MVP XL use to an outer diameter of 17 French and improved commercial execution. A real-world study at Emory involving more than 1,600 patients also showed that more than 92% were discharged on the same day, but the OEM business and the ensoETM product remained sources of pressure within Interventional Technologies.
On August 6, 2026, the company raised its reported revenue growth guidance for fiscal 2027 to 5%–8% and raised its organic growth range to 4%–7%. It also expects mid-single-digit growth in MedSurg, low- to mid-single-digit growth in Apheresis, and adjusted operating margin expansion of 50–100 basis points. It maintained free cash flow conversion guidance at approximately 80% of adjusted net income and its plasma collection volume growth assumption at 0%–2%.
Operating cash flow reached $52 million in Q1 fiscal 2027, approximately three times the comparable period, while free cash flow conversion reached 75% of adjusted net income. During the twelve months ended that quarter, conversion reached 106% of adjusted net income. The company ended the quarter with $223 million in cash and net leverage of approximately 2.69 times EBITDA, and repaid a total of $100 million of its credit facility during and after the quarter, leaving an outstanding balance of $200 million as of August 6, 2026.
The operating risks include a high degree of revenue dependence on Apheresis and Plasma, as Apheresis represented approximately 56% of Q1 fiscal 2027 revenue and Plasma accounts for nearly 80% of it. Adjusted operating margin also declined 70 basis points year over year to 23.4%, amid pressures from transportation, oil prices, and materials inflation, while the Vascular Closure recovery requires continued account recapture and effective competition. The analysts’ target range of $85–$119 and the 52-week range of $47.32–$109.57 provide further evidence of the broad uncertainty surrounding the sustainability of growth and margins.
